Researcher
Liselore Loverix
- Disciplines:Gynaecology, Obstetrics
Affiliations
- Gynaecological Oncology (Division)
Member
From15 Aug 2019 → Today
Projects
1 - 3 of 3
- Homologous Recombination Deficiency (HRD) as predictive and prognostic genetic marker in ovarian cancer - Bridging the gap between ‘one-size-fits-all’ and a more personalised treatment approachFrom1 Jun 2024 → TodayFunding: BOF - various
- Liquid biopsy and HRD testing in ovarian cancerFrom4 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 14
- Homologous Recombination Deficiency as predictive and prognostic genetic marker in ovarian cancer. Bridging the gap between ‘one-size-fits-all’ and a more personalised treatment approach.(2023)
Authors: Liselore Loverix, Toon Van Gorp, Diether Lambrechts, Ignace Vergote
- PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial(2023)
Authors: Liselore Loverix, Ignace Vergote, Pieter Busschaert, Tom Venken, Bram Boeckx, Hilde Brems, Els Van Nieuwenhuysen, Thaïs Baert, Sileny Han, Patrick Neven, et al.
Pages: 131 - 139 - A pan-cancer single-cell tumor micro-environment atlas predictive of immunotherapy response(2023)
Authors: Sam Vanmassenhove, Pierre Van Mol, Sarah Cappuyns, Liselore Loverix, Hanne Vos, Diether Lambrechts
- CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study(2023)
Authors: Diether Lambrechts, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Ignace Vergote
Pages: 697 - 713 - Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer(2022)
Authors: Pieter Busschaert, Siel Olbrecht, An Coosemans, Wouter Froyman, Liselore Loverix, Els Van Nieuwenhuysen, Sileny Han, Toon Van Gorp, Tom Venken, Ruben Heremans, et al.
- Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer(2022)
Authors: Liselore Loverix, Pieter Busschaert, Els Van Nieuwenhuysen, Sileny Han, Siel Olbrecht, Patrick Neven, Diether Lambrechts, Toon Van Gorp, Ignace Vergote
Pages: 14 - 22 - MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma(2022)
Authors: Diether Lambrechts, Liselore Loverix, Siel Olbrecht, Ignace Vergote
Pages: 855 - 871 - Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer-A Study of the OVCAD Consortium(2021)
Authors: Liselore Loverix, Toon Van Gorp, Ignace Vergote
- High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification(2021)
Authors: Siel Olbrecht, Pieter Busschaert, Jun Qian, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Sileny Han, An Coosemans, Anne-Sophie Van Rompuy, Diether Lambrechts, et al.
- The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium(2021)
Authors: Liselore Loverix, Ignace Vergote